Serial changes in myocardial fluorodeoxyglucose uptake on routine oncologic PET during breast cancer chemotherapy: are they clinically relevant?
OBJECTIVE: Cancer therapy-related cardiac dysfunction is an important prognostic factor in patients with breast cancer undergoing chemotherapy. We evaluated serial changes in myocardial fluorodeoxyglucose (FDG) uptake on routine oncologic PET and assessed whether these changes differed according to chemotherapy regimen. METHODS: We retrospectively analyzed 535 FDG PET examinations obtained before and after chemotherapy in 108 patients with breast cancer. Mean FDG uptake was measured in the myocardium with the highest accumulation and in the descending aorta on the same cross-section, and their ratio was defined as the myocardial standard uptake ratio (M-SUR). Chemotherapy regimens were classified as anthracyclines, human epidermal growth factor receptor 2 (HER2) inhibitors, immune checkpoint inhibitors (ICI), and others. Pre- and post-treatment M-SUR values were compared using the paired t-test. RESULTS: A total of 309 paired examinations were analyzed: anthracyclines, 34 pairs (n = 17); HER2 inhibitors, 146 pairs (n = 40); ICI, 20 pairs (n = 9); and others, 109 pairs (n = 54). M-SUR significantly increased after anthracycline therapy (3.45 ± 2.44 to 5.37 ± 3.67, P = 0.046) and ICI therapy (3.78 ± 2.94 to 4.98 ± 4.27, P = 0.0328). No significant change was observed in the HER2 inhibitor or other regimen groups. CONCLUSION: Serial FDG PET demonstrated regimen-dependent increases in myocardial FDG uptake after anthracycline and ICI therapy. Routine oncologic PET may reflect chemotherapy-related myocardial metabolic alterations.
Authors
- Yui Maekawa (ORCID: https://orcid.org/0009-0009-7170-5941)
- Yoko Satoh (ORCID: https://orcid.org/0000-0002-0188-0906)
- Yukako Izoe (ORCID: https://orcid.org/0000-0002-5321-7751)
- Hiroko Tsukada (ORCID: https://orcid.org/0000-0002-0147-9119)
- Hideyuki Saya (ORCID: https://orcid.org/0000-0001-6610-1902)
- Atsushi Yamamoto (ORCID: https://orcid.org/0000-0003-3020-260X)
- Shuji Sakai (ORCID: https://orcid.org/0000-0002-9237-9462)
- Satoki Watanabe (ORCID: https://orcid.org/0000-0003-1356-6364)
- Michinobu Nagao (ORCID: https://orcid.org/0000-0001-6049-8857)
- Sadako Akashi‐Tanaka (ORCID: https://orcid.org/0000-0002-2065-7742)
- Ryotaro Ando (ORCID: https://orcid.org/0009-0002-4943-0231)
Institutions
- Fujita Health University (JP)
- Fujita Health University Hospital (JP)
- Tokyo Women's Medical University (JP)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1097/mnm.0000000000002220
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00